MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ventyx Biosciences, Inc. - Common Stock (NQ:VTYX)

13.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ventyx Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why LendingClub Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Ventyx Biosciences Stock: Retail Buzz Spikes After Phase 2 Win In Obesity And Heart Risk Study ↗
The Phase 2 trial showed VTX3232 cut key inflammation markers like hsCRP by about 78% and IL-6 to below risk thresholds, reinforcing its anti-inflammatory potential. 
Via Stocktwits
News headline image
Why Ventyx (VTYX) Shares Soared 86.5% After Hours? ↗
Ventyx shares jumped 86.5% in after-hours trading after positive Phase 2 trial results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Wednesday? ↗
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
From Ventyx Biosciences, Inc.
Via GlobeNewswire
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Ventyx (VTYX) Q2 Net Loss Drops 16% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Thursday? ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences ↗
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease. 
Via Benzinga
News headline image
VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q2 2024 ↗
VTYX stock results show that Ventyx Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Dow Edges Lower; Ventyx Biosciences Shares Plummet ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump ↗
 
Via Benzinga
News headline image
Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further ↗
Ventyx Biosciences stock down over 24% on Monday after Phase 2 trial results for Crohn's disease drug VTX958 did not meet primary endpoint. 
Via Benzinga
News headline image
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q1 2024 ↗
VTYX stock results show that Ventyx Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
VTYX DEADLINE TODAY: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story